Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain.

@article{Grau2005CosteffectivenessAO,
  title={Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain.},
  author={Santiago Grau and Francisco {\'A}lvarez-Lerma and Almudena Del Castillo and R Neipp and Carlos Rubio-Terr{\'e}s},
  journal={Journal of chemotherapy},
  year={2005},
  volume={17 2},
  pages={
          203-11
        }
}
UNLABELLED The aim of this study was to assess the cost-effectiveness of linezolid (LIN) versus vancomycin (VAN) for the treatment of ventilator-associated pneumonia (VAP) using a decision model analysis from the National Health System perspective. Patients and participants comprising four subgroups were analyzed: all, Gram-positive (GP), Staphylococcus aureus (SA), methicillin-resistant SA (MRSA). The treatments were LIN 600 mg i.v., every 12 hours, 10 days and VAN 1,000 mg i.v., every 12… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Similar Papers

Loading similar papers…